Aflibercept (VEGF trap-eye): The newest anti-VEGF drug

British Journal of Ophthalmology

Volumn 96, Issue 9, 2012, Pages 1157-1158

  Stewart, Michael W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; APTAMER; BEVACIZUMAB; PLACENTAL GROWTH FACTOR; RANIBIZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 165; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VEGF TRAP EYE;

COMPARATIVE EFFECTIVENESS; DRUG COST; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG MARKETING; DRUG RECEPTOR BINDING; DRUG SAFETY; EDITORIAL; HEART INFARCTION; HUMAN; HYPERTENSION; NEUROBLASTOMA; NONHUMAN; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; PROTEINURIA; RETINA MACULA AGE RELATED DEGENERATION; STROKE; SUBRETINAL NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; HUMANS; RECOMBINANT FUSION PROTEINS; RETINAL DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84866091781     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2011-300654     Document Type: Editorial

References (12)

1. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002;99:11393e8.
2. R1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 2003;195:241e8.
3. http://newsroom.regeneron.com/releasedetail.cfm? ReleaseID=551570 (accessed 19 Nov 2011).
4. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419e31.
5. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular agerelated macular degeneration. N Engl J Med 2006;355:1432e44.
6. CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897e908.
7. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008;92:667e8.
8. Kim ES, Serur A, Huang J, et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A 2002;99:11399e404.
9. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008;145:239e48.
10. Heier JS, Boyer D, Nguyen QD, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 2011;118:1098e106.
11. Nguyen QD, Shah SM, Hafiz G, et al; CLEAR-AMD 1 Study Group. A phase 1 trial of intravenously administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:1522e32.
12. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112:1035e47.